Nuclear medical imaging (NMI) is the branch of nuclear medicine aimed at imaging the in-vivo distribution of specific compounds labeled with radioactive elements (radiotracers) inside animals (preclinical applications) or patients (clinical applications). These compounds are developed to follow metabolic pathways or for binding to receptor systems of interest and are administered to the imaged subject to obtain diagnostic information, such as the functionality of certain organs or the presence of tissues with altered metabolism, e.g. tumors or inflamed tissues. The estimation of the radiotracer distribution is obtained by externally detecting the radiations emitted by the radioactive element attached to the tracer...
|Qualification||Doctor of Philosophy|
|Award date||22 Dec 2021|
|Publication status||Published - 2021|
FundingThe research was funded by the European Commission through the EU FP7 project SUBLIMA, Grant Agreement 241711
- monolithic scintillator detector